Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30488768 | 1.00 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL232030 | 1.00 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL5193882 | 0.97 | NOS2 (0.94) | NOS2NOS1 | |
| SCHEMBL5190627 | 0.96 | NOS2 (0.93) | NOS2NOS1 | |
| SCHEMBL5191684 | 0.93 | NOS2 (0.87) | NOS2NOS1 | |
| SCHEMBL5190606 | 0.91 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL5192700 | 0.90 | NOS2 (1.00) | NOS2NOS1 | |
| SCHEMBL5190674 | 0.89 | NOS2 (0.81) | NOS2NOS1 | |
| SCHEMBL5193056 | 0.88 | NOS2 (0.94) | NOS2NOS1 | |
| SCHEMBL5194323 | 0.88 | NOS2 (0.78) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-0968206-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2006-11-15 | — | — | EP | claimed |
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-15 | — | — | US | claimed |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-24 | — | — | US | claimed |
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | claimed |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | claimed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | claimed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | claimed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | claimed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | claimed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | claimed |
| WO-2011144501-A1 | CCR2 ANTAGONISTS AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-24 | — | — | WO | disclosed |
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-0968206-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030078265-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885NOS1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.